KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Long-Term Deferred Tax (2018 - 2020)

Historic Long-Term Deferred Tax for Ionis Pharmaceuticals (IONS) over the last 5 years, with Q3 2020 value amounting to $307.7 million.

  • Ionis Pharmaceuticals' Long-Term Deferred Tax rose 797.9% to $307.7 million in Q3 2020 from the same period last year, while for Sep 2020 it was $307.7 million, marking a year-over-year increase of 797.9%. This contributed to the annual value of $305.6 million for FY2019, which is 507.61% up from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Long-Term Deferred Tax stood at $307.7 million for Q3 2020, which was up 797.9% from $306.0 million recorded in Q2 2020.
  • Ionis Pharmaceuticals' 5-year Long-Term Deferred Tax high stood at $309.6 million for Q1 2020, and its period low was $276.4 million during Q2 2019.
  • In the last 3 years, Ionis Pharmaceuticals' Long-Term Deferred Tax had a median value of $298.2 million in 2018 and averaged $294.8 million.
  • In the last 5 years, Ionis Pharmaceuticals' Long-Term Deferred Tax skyrocketed by 507.61% in 2019 and then skyrocketed by 1167.44% in 2020.
  • Over the past 3 years, Ionis Pharmaceuticals' Long-Term Deferred Tax (Quarter) stood at $290.8 million in 2018, then rose by 5.08% to $305.6 million in 2019, then increased by 0.71% to $307.7 million in 2020.
  • Its Long-Term Deferred Tax stands at $307.7 million for Q3 2020, versus $306.0 million for Q2 2020 and $309.6 million for Q1 2020.